Literature DB >> 2468045

Effects of oestrogen and the antioestrogens, tamoxifen and LY117018, on four oestrogen-regulated RNAs in the EFM-19 breast cancer cell line.

B R Westley1, F Hölzel, F E May.   

Abstract

The EFM-19 cell line is a new breast cancer cell line whose proliferation has been reported to be stimulated by oestrogens and inhibited by the antioestrogen tamoxifen. Oestrogen receptor mRNA levels are higher in EFM-19 cells than in other oestrogen-responsive cell lines. The levels of four oestrogen-inducible RNAs [pNR-1, pNR-2, pNR-25 and pNR-100] were measured in EFM-19 cells. Oestradiol treatment increased the levels of the four regulated RNAs between 3-fold (pNR-100) and greater than 100-fold (pNR-2). The induction was half maximal between 1.5 x 10(-11) and 1.5 x 10(-10) M oestradiol. The effects of two antioestrogens, tamoxifen and LY117018, were measured on the expression of the oestrogen-regulated RNAs. Tamoxifen was a partial oestrogen agonist for the induction of the pNR-1 and pNR-25 RNAs but had very little effect on the pNR-2 and pNR-100 RNA levels. The pNR-2 RNA levels were less induced by tamoxifen in EFM-19 cells than in MCF-7 cells. LY117018 did not increase the levels of any RNA. The oestrogen-induced levels of the four RNAs were reduced by both antioestrogens to the RNA levels present in cells treated with the antioestrogens alone. LY117018 was at least 100-fold more potent than tamoxifen as an oestrogen antagonist.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2468045     DOI: 10.1016/0022-4731(89)90208-2

Source DB:  PubMed          Journal:  J Steroid Biochem        ISSN: 0022-4731            Impact factor:   4.292


  9 in total

1.  Molecular mechanism of inhibition of estrogen-induced cathepsin D gene expression by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in MCF-7 cells.

Authors:  V Krishnan; W Porter; M Santostefano; X Wang; S Safe
Journal:  Mol Cell Biol       Date:  1995-12       Impact factor: 4.272

2.  Effects of tamoxifen on human breast cancer cells in vitro.

Authors:  W E Simon; G Trams; F Hölzel
Journal:  Arch Gynecol Obstet       Date:  1993       Impact factor: 2.344

3.  pS2--a new cytosolic protein recognized by monoclonal antibodies as a marker of hormone sensitivity in breast cancer.

Authors:  M Correale; I Abbate; A Paradiso; F Schittulli; C D Dragone; T Tedone; G Gargano; A M Catino; M D Musci; M De Lena
Journal:  Cell Biophys       Date:  1993 Jan-Jun

4.  Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen.

Authors:  M Berry; D Metzger; P Chambon
Journal:  EMBO J       Date:  1990-09       Impact factor: 11.598

5.  Insulin-like growth factor-dependent proliferation and survival of triple-negative breast cancer cells: implications for therapy.

Authors:  Zoë Davison; Gail E de Blacquière; Bruce R Westley; Felicity E B May
Journal:  Neoplasia       Date:  2011-06       Impact factor: 5.715

6.  Effects of celecoxib and ly117018 combination on human breast cancer cells in vitro.

Authors:  Klaus H Baumann; Elmar Klusmeier; Isabel Eggemann; Silke Reinartz; Achim Almeroth; Mathias Kalder; Uwe Wagner
Journal:  Breast Cancer (Auckl)       Date:  2009-04-07

7.  Expression of the oestrogen regulated pNR-2 mRNA in human breast cancer: relation to oestrogen receptor mRNA levels and response to tamoxifen therapy.

Authors:  J A Henry; S Nicholson; C Hennessy; T W Lennard; F E May; B R Westley
Journal:  Br J Cancer       Date:  1990-01       Impact factor: 7.640

8.  pNR-2/pS2 immunohistochemical staining in breast cancer: correlation with prognostic factors and endocrine response.

Authors:  J A Henry; N H Piggott; U K Mallick; S Nicholson; J R Farndon; B R Westley; F E May
Journal:  Br J Cancer       Date:  1991-04       Impact factor: 7.640

9.  Determination of oestrogen responsiveness of breast cancer by competitive reverse transcription-polymerase chain reaction.

Authors:  M Carr; F E May; T W Lennard; B R Westley
Journal:  Br J Cancer       Date:  1995-12       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.